• Models of Investigation
• 41 min
  1. Antifungal innate immunity in C. elegans

  • Dr. Jonathan Ewbank
• 44 min
  2. The anti-microbial defense of Drosophila: a paradigm for innate immunity

  • Prof. Jules Hoffmann
• 38 min
  3. Phagocytosis in the fruit fly, Drosophila melanogaster

  • Dr. Lynda Stuart
• 62 min
  4. Innate immune sensing and response

  • Prof. Bruce Beutler
• 61 min
  5. Macrophages and systems biology

  • Prof. David Hume
• Cell Types and Recruitment
• 71 min
  6. Leukocyte recruitment in vivo

  • Prof. Paul Kubes
• 51 min
  7. Chemokines and inflammation: a critical assessment of therapeutic targets

  • Dr. David Greaves
• 42 min
  8. Eosinophils

  • Prof. Tim Williams
• 63 min
  9. Dendritic cells: linking innate to different forms of adaptive immunity

  • Prof. Ralph Steinman
• 25 min
  10. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmunity

  • Prof. Yong-Jun Liu
• 61 min
  11. Innate-like lymphocytes 1

  • Prof. Adrian Hayday
• 41 min
  12. Innate-like lymphocytes 2

  • Prof. Adrian Hayday
• Recognition and Signaling
• 50 min
  13. Colony stimulating factor-1 regulation of macrophages in development and disease

  • Prof. E. Richard Stanley
• 42 min
  14. Fc receptors: linking innate and acquired immunity

  • Prof. Ken G C Smith
• 39 min
  15. Phagocytosis

  • Prof. Joel Swanson
• 44 min
  16. Clearance of apoptotic cells and the control of inflammation

  • Prof. Sir John Savill
• 38 min
  17. Signaling by innate immune receptors

  • Prof. Michael Karin
• 41 min
  18. Nuclear receptors at the crossroads of inflammation and atherosclerosis

  • Prof. Christopher Glass
• Modulation of Effector Responses
• 22 min
  19. Humoral innate immunity and the acute phase response 1

  • Prof. Alberto Mantovani
• 42 min
  20. Humoral innate immunity and the acute phase response 2

  • Prof. Alberto Mantovani
• 54 min
  21. Cytokines regulating the innate response

  • Prof. Anne O’Garra
• 39 min
  22. Arginase and nitric oxide

  • Dr. Peter Murray
• 38 min
  23. Novel lipid mediators in resolution of inflammation

  • Prof. Charles Serhan
• 69 min
  24. Resolvins activate inflammation-resolution programs: a systems approach to resolution

  • Prof. Charles Serhan
• 42 min
  25. Cationic peptides in innate immunity

  • Dr. Dawn Bowdish
• 27 min
  26. Iron metabolism and innate immunity

  • Prof. Tomas Ganz
• Pathogen-Host Interactions
• 46 min
  27. Innate recognition of viruses

  • Prof. Caetano Reis e Sousa
• 50 min
  28. Type I interferons in innate immunity to viral infections

  • Prof. Christine Biron
• 56 min
  29. HIV-1 and immunopathogenesis: innate immunity

  • Prof. Luis Montaner
• 53 min
  30. Understanding and combating tuberculosis

  • Prof. David Russell
• 34 min
  31. The taste of a fungus: recognition of Candida by the innate immune system

  • Prof. Neil Gow
• 51 min
  32. Innate immunity and malaria

  • Prof. Douglas Golenbock
• Health and Disease
• 39 min
  33. Innate immunity in children

  • Prof. David Speert
• 59 min
  34. From bench to bedside: evolution of anti-TNFalpha therapy in rheumatoid arthritis

  • Prof. Sir Ravinder Maini
• 33 min
  35. NOD-like receptors in innate immunity and inflammatory disease

  • Prof. Gabriel Nunez
• 38 min
  36. Paneth cells in innate immunity and inflammatory bowel disease

  • Prof. Satish Keshav
• 36 min
  37. Innate immunity in the brain in health and disease

  • Prof. V. Hugh Perry
• 54 min
  38. The fate of monocytes in atherosclerosis

  • Prof. Gwendolyn Randolph
• 49 min
  39. Macrophages, a cellular toolbox used by tumors to promote progression and metastasis

  • Prof. Jeffrey Pollard
• Archived Lectures *These may not cover the latest advances in the field
• 73 min
  40. Monocyte/macrophages in innate immunity

  • Prof. Emeritus Siamon Gordon
• 32 min
  41. Innate immunity in C. elegans

  • Dr. Jonathan Ewbank
• 51 min
  42. Antigen processing and presentation: modulation by innate immune signals

  • Prof. Colin Watts
• 39 min
  43. NLR genes: infection, inflammation and vaccines

  • Prof. Jenny Ting
• 63 min
  44. Manipulation of innate immune response: lessons from shigella

  • Prof. Philippe Sansonetti
• 35 min
  45. Innate immunity of the lung and adaptation to air breathing at birth

  • Prof. Jeffrey Whitsett

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Overview of presentation
3. Early experiments
4. Human cytokines in 1980s
5. Properties of cytokines
6. TNFalpha at a protein and a genomic level
7. TNFalpha and anti-TNFalpha antibodies
8. The location of the TNFalpha gene
9. TNF and lymphotoxin bind to shared receptors
10. Rheumatoid arthritis: burden of disease
11. RA - structural and molecular deformities
12. Pathology of RA
13. Key members of the KIR team
14. IL-1 and TNFalpha in RA
15. RA synovium's IL-1alpha synthesis
16. Importance of TNF in cytokine regulation in vitro
17. TNF and receptors in RA tissues
18. Anti TNF treatment in an animal model of RA
19. Cytokine cascade in RA
20. A molecular hypothesis
21. First anti-TNF (cA2/infliximab) in RA clinical trials
22. Infliximab's mechanism of action
23. Anti-TNF works and tolerated well (1992)
24. Initial RCT of anti-TNF therapy (infliximab) in RA
25. How does anti-TNF work?
26. Reduction of acute phase response by infliximab
27. Anti-TNF regulates IL-6 in RA in vivo
28. Anti-TNF therapy reduces cellularity
29. Reduction in synovial inflammatory cell infiltrate
30. Why is cellularity reduced?
31. Adhesion molecules on infliximab therapy
32. Serum E-selectin levels are reduced after anti-TNF
33. Infliximab effect on specific chemokines
34. Synovial biopsies before and after anti-TNF therapy
35. Anti-TNF and angiogenesis
36. Anti-TNF reduces retention/recruitment of WBC
37. Anti-TNF reduces vascularity
38. Proposed mechanisms of action
39. Infliximab regulates altered T and B cell immunity
40. Summary of biological effects of infliximab
41. Anti-TNF biologicals in the clinic
42. Efficacy in randomised clinical trials
43. Anti-TNF therapy in other diseases
44. Adverse events and safety issues
45. Limitations of anti-TNF therapy
46. After TNF: what are we looking for?

Topics Covered

• What are cytokines?
• Early experiments
• Human cytokines in the 1980s
• Identification of TNFalpha at protein and genomic level
• TNFalpha and anti-TNFalpha antibodies
• Rheumatoid arthritis (RA): burden of disease
• Pathology of RA
• IL-1 and TNFalpha
• Cytokine cascade in RA
• A molecular hypothesis
• First anti-TNF (cA2/infliximab) in clinical trials in RA
• How does anti-TNF work?
• Why is cellularity reduced?
• Anti-TNF therapy inhibits cartilage and especially bone destruction
• Infliximab regulates altered T and B cell immunity
• Biological effects of Infliximab
• Anti-TNF biologicals in the lab
• Efficacy in randomized clinical trials
• Effective anti-TNF therapy demonstrates shared TNF-pathways in other diseases
• Adverse events and safety issues
• Limitations of anti-TNF therapy
• After TNF: what are we looking for?

Links

Series:

• Innate Immunity

Categories:

• Clinical Practice
• Immunology
• Pharmaceutical Sciences

Therapeutic Areas:

• Immunology & Inflammation

Talk Citation

Publication History

• Published on May 31, 2009
• Archived on May 28, 2025

Financial Disclosures

• Prof. Sir Ravinder Maini has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.